Mind Cure announces a health-and-wellness supplement to support teen mental health.
Mind Cure announces a health-and-wellness supplement to support teen mental health.
After a great year in 2020, psychedelic drug stocks are poised for an even better year in 2021.
2020 was a very good year for the psychedelic drug industry. Psychedelic Stock Watch has compiled our own Report Card on industry performance.
Psychedelic drugs have the potential to revolutionize mental health care while simultaneously saving the global economy $100s of billions each year.
Numinus announces the first legal extraction of psilocybe mushrooms in Canada by a public company.
After some early turbulence in 2020, psychedelic drug stocks have taken off.
MindMed increases its latest bought-deal financing to CAD$80 million.
Numinus acquires a Montreal-based provider of psychedelic-assisted psychotherapies.
MindMed continues to raise capital. This time issuing 11,364,000 units at CAD$4.40 for gross proceeds of CAD$50,001,600.
MindMed announces a successful pre-Investigational New Drug meeting with the FDA regarding its Project Lucy (LSD) research for anxiety.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now